MedPath

A Study to Evaluate the Product Performance of a Low Add MultiFocal Soft Contact Lens

Not Applicable
Completed
Conditions
Presbyopia
Interventions
Device: PureVision multifocal contact lens
Device: LD118033 contact lens
Registration Number
NCT01539694
Lead Sponsor
Bausch & Lomb Incorporated
Brief Summary

The objective of this study is to evaluate the product performance of an investigational multifocal low add soft contact lens.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
126
Inclusion Criteria
  • Have physiologically normal anterior segments.
  • Be adapted wearers of soft contact lenses and wear a lens in each eye.
  • Be presbyopic and require near add correction in each eye.
  • Have no active ocular disease or allergic conjunctivitis.
  • Must not be using any topical ocular medications.
Exclusion Criteria
  • Any Grade 2 or greater finding during the slit lamp examination.
  • Any scar or neovascularization within the central 4mm of the cornea.
  • Any "Present" finding during the slit lamp examination that, in the Investigator's judgment, interferes with contact lens wear.
  • Allergic to any component in the study products.
  • Any systemic disease affecting ocular health.
  • Using any systemic or topical medications that will affect ocular physiology or lens performance.
  • An active ocular disease, any corneal infiltrative response or are using any ocular medications.

Study & Design

Study Type
INTERVENTIONAL
Study Design
CROSSOVER
Arm && Interventions
GroupInterventionDescription
PureVision multifocal contact lensPureVision multifocal contact lensPureVision multifocal low add soft contact lens, to be worn on a daily wear basis.
LD118033 contact lensLD118033 contact lensInvestigational LD118033 multifocal low add soft contact lenses, to be worn on a daily wear basis.
Primary Outcome Measures
NameTimeMethod
Visual AcuityAt 1 week follow up

Visual acuity was assessed by distance high contrast logarithm of the minimum angle of resolution (logMAR).

Secondary Outcome Measures
NameTimeMethod
Symptoms/ComplaintsAt 1 week follow up

Symptoms/complaints were assessed on a scale from 0 to 100, with 0 denoting unfavorable symptoms/complaints.

Trial Locations

Locations (1)

Bausch & Lomb Incorporated

🇺🇸

Rochester, New York, United States

© Copyright 2025. All Rights Reserved by MedPath